On Monday, Shares of Mattel, Inc. (NASDAQ:MAT), gained 8.48% to $21.62, as the company prepares for its November release of a $75 high-tech Hello Barbie Doll.
With sales of Mattel’s 56-year-old Barbie doll set for a fourth annual decline and down 16% during the first half of 2015, the company hopes its introduction of a high-tech Barbie doll will assist reverse losses, the New York Post reports.
Mattel claims its new Hello Barbie Doll will be able to deliver 8,000 lines of conversation, which the company hopes will broaden the doll’s appeal to children aged 3-to-9 from children aged 3-to-6, according to the Post.
MATTEL, INC. designs, manufactures, and markets a variety of toy products around the world, which are sold to its customers and directly to consumers. The Company operates through three segments: North America, which consists of the United States and Canada, International, and American Girl.
Shares of Vringo, Inc. (NASDAQ:VRNG), declined -41.10% to $0.321, during its last trading session.
Vringo, issued a statement to shareholders.
“We remain confident in our licensing, litigation and innovation strategies. Administration remains committed to rebuilding shareholder value and confidence,” said Andrew Perlman, Chief Executive Officer of Vringo. “Given the exceptionally low historical odds of being heard at the Supreme Court, we believe that the decline in today’s share price does not accurately reflect the change in Vringo`s underlying value.”
“The decision by the Supreme Court does not have any effect on the over 600 patents and applications in Vringo`s patent portfolios. We continue our global litigation against ZTE, which remains unaffected by today’s decision, and which to date, has achieved positive results and rulings in many countries around the world. While ZTE is a large player in the telecommunications infrastructure and handset industries, it represents a small percentage of the revenue that is generated from sales of those products.”
Vringo, Inc. is a development-stage company. The Company is focused on identifying, generating, acquiring, and deriving economic benefits from intellectual property assets. It intends to monetize its technology portfolio through a range of initiatives, including licensing, strategic partnerships and litigation.
Shares of Adobe Systems Incorporated (NASDAQ:ADBE), inclined 2.20% to $85.84, during its last trading session.
At Adobe MAX 2015, the world’s leading creativity conference, Adobe (Nasdaq:ADBE) recently released findings from a survey of more than 2,000 U.S. consumers that shows standards for digital content are rising as people are inundated with content across multiple devices. The report, “The State of Content: Expectations on the Rise,” highlights consumers’ changing attitudes about content, counting a growing skepticism about online content, and reveals a new imperative for brands and creators to develop content that is well-designed, easily accessible and authentic.
According to the study, consumers are embracing content across screens. They are accessing an average of 12 sources of content through an average of six different devices, with smartphones ranking as the most frequently used device by Millennials daily. Eighty-eight percent of consumers report they “multiscreen,” using an average of nearly three devices simultaneously. Forty percent find this deluge of information distracting.
Adobe Systems Incorporated (Adobe) is a software company. The Company offers products and services for professionals, marketers, application developers, enterprises and consumers for creating, managing, delivering, optimizing and engaging with content. Adobe markets and licenses its products and services through app stores and its Website www.adobe.com.
Finally, Inovio Pharmaceuticals Inc (NASDAQ:INO), ended its last trade with 4.06% gain, and closed at $6.15.
Inovio Pharmaceuticals, declared recently that administration will take part at three forthcoming investor conferences in October and November:
Aegis Growth Conference, October 7-9, 2015, Las Vegas, Nevada.
Inovio Pharmaceuticals, Inc. (Inovio) is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. As of December 31, 2014, Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, influenza and Ebola.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
